382 related articles for article (PubMed ID: 37446024)
61. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature.
Green EA; Li R; Albiges L; Choueiri TK; Freedman M; Pal S; Dyrskjøt L; Kamat AM
Eur Urol Oncol; 2021 Dec; 4(6):893-903. PubMed ID: 33975782
[TBL] [Abstract][Full Text] [Related]
62. Predicting progression of bladder urothelial carcinoma using microRNA expression.
Rosenberg E; Baniel J; Spector Y; Faerman A; Meiri E; Aharonov R; Margel D; Goren Y; Nativ O
BJU Int; 2013 Nov; 112(7):1027-34. PubMed ID: 23387295
[TBL] [Abstract][Full Text] [Related]
63. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma.
Khella HW; Bakhet M; Allo G; Jewett MA; Girgis AH; Latif A; Girgis H; Von Both I; Bjarnason GA; Yousef GM
Carcinogenesis; 2013 Oct; 34(10):2231-9. PubMed ID: 23715501
[TBL] [Abstract][Full Text] [Related]
64. Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer.
Chan E; Garg K; Stohr BA
Mod Pathol; 2020 Sep; 33(9):1802-1810. PubMed ID: 32313185
[TBL] [Abstract][Full Text] [Related]
65. miRNA and cancer; computational and experimental approaches.
Tutar Y
Curr Pharm Biotechnol; 2014; 15(5):429. PubMed ID: 25189575
[TBL] [Abstract][Full Text] [Related]
66. MicroRNAs as new diagnostic and prognostic biomarkers in urological tumors.
Fendler A; Jung K
Crit Rev Oncog; 2013; 18(4):289-302. PubMed ID: 23614616
[TBL] [Abstract][Full Text] [Related]
67. [Urologic tumors in old age].
Debruyne FM
Tijdschr Gerontol Geriatr; 1986 Apr; 17(2):65-8. PubMed ID: 3715964
[TBL] [Abstract][Full Text] [Related]
68. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T
Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703
[TBL] [Abstract][Full Text] [Related]
69. [MicroRNAs as potential noninvasive markers in the diagnosis of urological malignancies].
Gilyazova IR; Klimentova EA; Pavlov VN; Khusnutdinova EK
Urologiia; 2016 Apr; (2):96-102. PubMed ID: 28247670
[TBL] [Abstract][Full Text] [Related]
70. Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma.
Xiong G; Liu J; Tang Q; Fan Y; Fang D; Yang K; Xie F; Zhang M; Zhang L; Liu L; Zhang C; Yao L; Yang L; Ci W; Zhao W; Gong Y; He Q; Gong K; He Z; Wang G; Li X; Guo Y; Zhou L
Epigenomics; 2015 Aug; 7(5):733-44. PubMed ID: 25912368
[TBL] [Abstract][Full Text] [Related]
71. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
Saito K; Kihara K
Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
[TBL] [Abstract][Full Text] [Related]
72. Diagnostic Value of MicroRNAs for Urologic Cancers: A Systematic Review and Meta-Analysis.
Ouyang H; Zhou Y; Zhang L; Shen G
Medicine (Baltimore); 2015 Sep; 94(37):e1272. PubMed ID: 26376375
[TBL] [Abstract][Full Text] [Related]
73. Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC.
Szabó Z; Szegedi K; Gombos K; Mahua C; Flaskó T; Harda K; Halmos G
Urol Oncol; 2016 Dec; 34(12):533.e21-533.e27. PubMed ID: 27427222
[TBL] [Abstract][Full Text] [Related]
74. Connecting the dots between different networks: miRNAs associated with bladder cancer risk and progression.
Braicu C; Buiga R; Cojocneanu R; Buse M; Raduly L; Pop LA; Chira S; Budisan L; Jurj A; Ciocan C; Magdo L; Irimie A; Dobrota F; Petrut B; Berindan-Neagoe I
J Exp Clin Cancer Res; 2019 Oct; 38(1):433. PubMed ID: 31665050
[TBL] [Abstract][Full Text] [Related]
75. Differentially Expressed Extracellular Vesicle-Contained microRNAs before and after Transurethral Resection of Bladder Tumors.
Strømme O; Heck KA; Brede G; Lindholm HT; Otterlei M; Arum CJ
Curr Issues Mol Biol; 2021 Jun; 43(1):286-300. PubMed ID: 34199766
[TBL] [Abstract][Full Text] [Related]
76. Clinical utility of microRNAs in renal cell carcinoma: current evidence and future perspectives.
Tsiakanikas P; Giaginis C; Kontos CK; Scorilas A
Expert Rev Mol Diagn; 2018 Nov; 18(11):981-991. PubMed ID: 30345829
[TBL] [Abstract][Full Text] [Related]
77. microRNA expression profiles as decision-making biomarkers in the management of bladder cancer.
Amir S; Mabjeesh NJ
Histol Histopathol; 2017 Feb; 32(2):107-119. PubMed ID: 27586262
[TBL] [Abstract][Full Text] [Related]
78. Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice.
Blanca A; Cheng L; Montironi R; Moch H; Massari F; Fiorentino M; Raspollini MR; Scarpelli M; Lopez-Beltran A
Curr Drug Metab; 2017 Oct; 18(8):712-722. PubMed ID: 28524002
[TBL] [Abstract][Full Text] [Related]
79. Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer.
Juracek J; Peltanova B; Dolezel J; Fedorko M; Pacik D; Radova L; Vesela P; Svoboda M; Slaby O; Stanik M
J Cell Mol Med; 2018 Mar; 22(3):2033-2038. PubMed ID: 29363887
[TBL] [Abstract][Full Text] [Related]
80. Expression profile of microRNAs in bladder cancer and their application as biomarkers.
Taheri M; Shirvani-Farsani Z; Ghafouri-Fard S; Omrani MD
Biomed Pharmacother; 2020 Nov; 131():110703. PubMed ID: 32890965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
